Hitchhiking cancer vaccine makes progress in the clinic
MIT spinout Elicio developed a vaccine based on a lymph node-targeting approach first developed at the Koch Institute. Phase 1 solid tumor clinical trial results are promising so far.
MIT spinout Elicio developed a vaccine based on a lymph node-targeting approach first developed at the Koch Institute. Phase 1 solid tumor clinical trial results are promising so far.
Award honors “scientists who have made a transformational contribution toward the improvement of human health.”
A new microscopy technique that enables high-resolution imaging could one day help doctors diagnose and treat brain tumors.
Using a DNA-based scaffold carrying viral proteins, researchers created a vaccine that provokes a strong antibody response against SARS-CoV-2.
Faculty and researchers across MIT’s School of Engineering receive many awards in recognition of their scholarship, service, and overall excellence.
Twelve researchers selected as finalists for 2023-24 MIT-Royalty Pharma Prize Competition to support female entrepreneurs in biotech.
A compound originally developed to treat cancer could be repurposed to treat polycystic kidney disease, an inherited condition that can lead to kidney failure.
MIT researchers can now track a cell’s RNA expression to investigate long-term processes like cancer progression or embryonic development.
MIT Koch Institute researchers Daniel Anderson and Ana Jaklenec, plus 11 MIT alumni, are honored for inventions that have made a tangible impact on society.
These compounds can kill methicillin-resistant Staphylococcus aureus (MRSA), a bacterium that causes deadly infections.
MIT researchers find that in mice and human cell cultures, lipid nanoparticles can deliver a potential therapy for inflammation in the brain, a prominent symptom in Alzheimer’s.
MIT professor combines nanoscience and viruses to develop solutions in energy, environment, and medicine.
A new method enables optical devices that more closely match their design specifications, boosting accuracy and efficiency.
Human volunteers will soon begin receiving an HIV vaccine that contains an adjuvant developed in Irvine’s lab, which helps to boost B cell responses to the vaccine.
Researchers are working to advance the field of glycoscience, illuminating the essential role of carbohydrates for human health and disease.